Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

• Status: Unknown status
• Trial end date: 2019-10-30
• Target enrollment: 0
• Participant gender: All

Summary

Undifferentiated thyroid cancer is the most malignant tumor of the thyroid gland, with a median survival of only 3 months. Most undifferentiated cancers lose the chance of surgery when they are first diagnosed. The current study, Nexavar, is used only for dedifferentiated thyroid cancer and has not been applied to undifferentiated cancer. This study attempted to apply it to preoperative treatment of undifferentiated cancer to see if it would shrink the tumor and give the patient an opportunity for surgery.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fujian Medical University
• Treatments: Niacinamide; Sorafenib

Criteria

Inclusion Criteria:

• Diagnosis of Undifferentiated or poorly differentiated thyroid cancer

• Tumor invades the trachea, esophagus or common carotid artery that are Unresectable.

• Locally recurrent anaplastic thyroid cancer

• The lesion size is greater than 3cm

• Patients in whom the oncologist has decide to start therapy with NEXAVAR.

Exclusion Criteria:

• Lesions cannot be evaluated by imaging

• Synonymous with contraindications to Nexavar.